Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AstraZeneca,University of Sydney
Scientific Title
A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)